ArticleImmunogenetics2025
Evaluation of lymphoid defects in specific inborn errors of immunity using a single-tube multicolor flow cytometry assay.
Article in Immunogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The present study aimed to evaluate lymphoid defects in patients with specific IEIs (n = 28) using a 12-antibody 9-color single-tube flow cytometry assay. The lymphoid defects (lymphocyte counts below the reference range) were significantly higher in XLA patients (p-0.0002), CVID patients (p-0.00022), WAS patients (p- < 0.001), HIES patients (p- < 0.001), CHS patients (p < 0.001), and CGD patients (p < 0.0002) than age-matched controls. The lymphoid defects (lymphocyte counts above the reference range) were significantly higher in LAD-1 than age-matched controls (p < 0.001). In patients with XLA, the NK cells were reduced in 50% and naïve Tc cells in 33.3% of patients. The patients with CVID showed reduced CD4 + T cell subset in 75% and increased memory Tc cells in 50% of patients. In WAS, absolute B cell, naïve B cell, switched memory B cell, CD4 + T cell, and naïve Th cell counts were decreased in 100% of patients. In HIES, the CD4 + T cell and memory Th cell count was reduced in 100% of patients. In CGD, reduced absolute count of T cells, CD4 + T cells, CD8 + T cells, naïve Th cells, memory Th cells, naïve Tc cells and γδ T cells and increased B-cell counts were noted in 67% of cases. Both B- and T-cell defects were identified in HIGM, MHC-II deficiency, LAD-1, CHS, CARD-11, and STXBP2 defects. No significant difference was observed between routine and single-tube panel results by paired T-test.
Indexed as
Identifiers
41238939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.